Mankind Pharma balance sheet

As of Sep 2026

Total assets: ₹28,954cr+0.5% on Sep 2025
Shareholders' equity: ₹17,855cr+15.0% on Sep 2025
Total debt: ₹5,422cr−35.2% on Sep 2025
Cash and investments: ₹2,547cr−11.4% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	3,037	2,960	2,908	2,932	2,524
	752	655	306	207	493
	0.1	0.1	0.1	5.3	5.4
	6,487	6,493	6,493	20.0	20.0
	8,883	9,168	9,604	1,588	1,701
	447	473	520	74.7	57.0
	204	200	191	189	—
	272	248	160	310	271
	54.0	64.5	200	29.5	110
	326	313	361	339	381
	289	325	108	80.4	29.8
	457	352	92.3	66.3	73.4
	20,883	20,937	20,582	5,313	5,285
	2,345	2,144	2,094	1,553	1,498
	1,433	1,537	1,691	2,258	1,075
	2,179	1,730	1,538	848	576
	1,114	392	407	382	305
	23.3	91.1	147	816	148
	2.7	4.3	4.0	2.9	1.6
	90.4	248	301	13.2	56.0
	4,842	4,002	4,089	4,320	2,163
	766	805	803	692	663
	8,069	7,140	7,175	6,648	4,427
	2.7	2.7	2.7	2.7	3.3
	28,954	28,080	27,760	11,963	9,715
Equity
	41.3	41.3	41.3	40.1	40.1
	17,541	16,259	14,291	9,323	7,395
	17,582	16,300	14,332	9,363	7,435
	273	261	236	213	188
	17,855	16,561	14,568	9,576	7,623
Liabilities
	3,101	2,893	5,540	32.6	28.3
	3,101	2,893	5,540	32.6	28.3
	264	249	155	123	97.9
	1,819	1,840	1,813	89.1	77.3
	29.9	29.9	20.0	23.0	25.5
	5,214	5,011	7,528	268	229
	2,320	3,419	2,971	175	142
	1,631	1,341	1,133	1,103	1,008
	849	749	674	236	236
	4,800	5,510	4,779	1,513	1,387
	869	814	664	389	308
	94.0	10.9	18.1	46.4	46.3
	121	173	203	171	123
	5,885	6,507	5,664	2,120	1,863
	11,099	11,518	13,191	2,387	2,092
	28,954	28,080	27,760	11,963	9,715
Assets — additional as-filed lines
	115	188	189	82.0	103
Trade payables — MSME split
	216	149	86.3	—	—
	1,415	1,193	1,047	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANKIND₹2,490.00

Mankind Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹1.03L Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	2,523.8	2,931.6	2,907.8	2,959.6	3,037.3
+ Capital Work-in-Progress	493.2	207.1	306.1	654.8	751.7
+ Investment Property	5.4	5.3	0.1	0.1	0.1
+ Goodwill	20.0	20.0	6,492.6	6,492.6	6,487.2
+ Other Intangibles	1,701.5	1,588.3	9,604.0	9,168.3	8,882.6
+ Intangibles under Development	57.0	74.7	519.5	472.9	447.0
+ Investments (Equity Method)	—	189.3	190.9	199.8	204.2
+ Non-current Investments	270.9	309.8	160.2	248.0	272.1
+ Other Non-current Financial Assets	110.2	29.5	200.3	64.5	54.0
Non-current Financial Assets	381.1	339.3	360.5	312.5	326.1
+ Deferred Tax Assets	29.8	80.4	107.9	324.7	289.3
+ Other Non-current Assets	73.4	66.3	92.3	352.0	457.3
Total Non-current Assets	5,285.1	5,313.0	20,581.8	20,937.1	20,882.8
Current Assets
+ Inventories	1,498.5	1,553.5	2,093.7	2,144.5	2,345.1
+ Current Investments	1,075.5	2,258.1	1,690.8	1,537.3	1,432.8
+ Trade Receivables	576.4	848.3	1,538.3	1,729.5	2,179.3
+ Cash & Cash Equivalents	304.8	382.0	407.4	391.7	1,113.8
+ Other Bank Balances	148.4	816.0	147.1	91.1	23.3
+ Short-term Loans	1.6	2.9	4.0	4.3	2.7
+ Other Current Financial Assets	56.0	13.2	301.4	247.9	90.4
Current Financial Assets	2,162.7	4,320.4	4,089.0	4,001.8	4,842.2
+ Other Current Assets	663.4	691.7	802.8	805.3	766.3
Total Current Assets	4,427.1	6,647.5	7,175.1	7,139.7	8,068.9
+ Assets Held for Sale	3.3	2.7	2.7	2.7	2.7
Total Assets	9,715.4	11,963.3	27,759.5	28,079.5	28,954.4
Equity
+ Equity Share Capital	40.1	40.1	41.3	41.3	41.3
+ Other Equity / Reserves	7,395.2	9,323.0	14,291.1	16,259.1	17,540.9
Equity — Owners of Parent	7,435.2	9,363.1	14,332.4	16,300.3	17,582.2
+ Minority Interest	188.1	212.7	235.8	260.7	273.0
Total Equity	7,623.3	9,575.8	14,568.2	16,561.1	17,855.2
Liabilities
+ Borrowings — Non-current	28.3	32.6	5,540.2	2,892.7	3,101.3
Non-current Financial Liabilities	28.3	32.6	5,540.2	2,892.7	3,101.3
+ Provisions — Non-current	97.9	123.1	155.1	248.7	264.4
+ Deferred Tax Liabilities	77.3	89.1	1,812.5	1,840.0	1,818.7
+ Other Non-current Liabilities	25.5	23.0	20.0	29.9	29.9
Non-current Liabilities	229.0	267.7	7,527.8	5,011.2	5,214.3
+ Borrowings — Current	142.0	174.6	2,971.2	3,418.9	2,320.4
+ Trade Payables	1,008.2	1,103.0	1,133.4	1,341.3	1,631.0
+ Other Current Financial Liab	236.5	235.5	674.2	749.5	848.9
Current Financial Liabilities	1,386.7	1,513.1	4,778.8	5,509.7	4,800.3
+ Provisions — Current	307.6	389.3	663.9	813.7	869.5
+ Current Tax Liabilities	46.3	46.4	18.1	10.9	94.0
+ Other Current Liabilities	122.5	170.9	202.8	172.9	121.0
Current Liabilities	1,863.1	2,119.7	5,663.6	6,507.3	5,884.8
Total Liabilities	2,092.2	2,387.5	13,191.4	11,518.5	11,099.1
Total Equity & Liabilities	9,715.4	11,963.3	27,759.5	28,079.5	28,954.4
Assets — additional as-filed lines
+ Current Tax Assets	102.5	82.0	189.5	188.2	115.3
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	86.3	148.7	216.1
+ Dues to Other Creditors — Current	—	—	1,047.1	1,192.6	1,414.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.